Sparta Systems launches cloud-based Stratas Quality Management

Sparta Systems, Inc., a producer of enterprise quality management software (EQMS) solutions, has launched its cloud-based Stratas Quality Management solution.

Utilizing 20 years of quality management experience from the previous TrackWise system, Stratas Quality Management has improved upon Sparta’s previous Startas platform to offer a quick-implementation program that organizations can use straight away. Features include improved scalability and increased security measures that meet the high demands of pharmaceutical, biotech and medical device industries.

The system, as an extension of existing Sparta cloud solutions, gives new options to the already 25,000 users and is already in use in many life science organizations. The system also adds upon the Sparta Quality Business Network (QBN), giving users additional access to the global network in order to improve visibility, collaboration, efficiency and compliance all while lowering risks.

“More life sciences companies are beginning to explore how they can use both hybrid and standalone QMS systems from Sparta to enhance quality throughout their organizations and products’ life cycles,” said Sparta Systems’ CEO Eileen Martinson. “For us, it’s all about offering customers choices that align to their strategies. For example, our large enterprise companies are moving to a hybrid model where they connect TrackWise to our newer cloud-based solutions. In the mid-market, companies are still using paper and spreadsheets to manage quality. These companies want a solution that is 100% cloud, with best practices from Sparta.  Hence, the addition of the Stratas QMS to our solution portfolio.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.